This study is designed to elucidate the relationship between virologic risk factors and immunologic and clinical progression in HIV+ subjects receiving ZDV or ddI, and to compare new treatment regimens with combinations of reverse transcriptase inhibitors in long-term recipients of monotherapy. This is a randomized, partially blinded trial for ACTG 175 participants who are on ZDV or ddI monotherapy at the time of enrollment into ACTG 302. Treatment goals are: to define the best nucleoside analog sequence and combination, to determine the reason for disease progression in the face of therapy, and to compare strategies for maintaining suppression of viral replication. Since ddI and ZDV induce different drug resistance mutations and may exert different effects on HIV, the treatment regimens offered in this trial depend on prior therapy in ACTG 175. For those participants unblinded to long term ZDV monotherapy, the study seeks to investigate two therapeutic strategies: 1) the addition of a new reverse transcriptase inhibitor, lamivudine (3TC) with ZDV, and 2) switching to monotherapy with stavudine (d4T). For those participants unblinded to long term ddI monotherapy, the addition of ZDV and 3TC may provide additional drug resistance. The addition of ZDV to subjects on long term ddI will provide a test of the hypothesis that the 215 and 74 mutations are incompatible within the same virus/subject when both drugs are sued. The interaction between 3TC and ddI could place even more selective pressure on the virus, resulting in either more virus suppression, or more rapid development of codon 184 and escape from both ddI and 3TC suppressive effects. This study is closed to enrollment as of 1/31/96.

Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1996
Total Cost
Indirect Cost
Chappell, Cynthia L; Darkoh, Charles; Shimmin, Lawrence et al. (2016) Fecal Indole as a Biomarker of Susceptibility to Cryptosporidium Infection. Infect Immun 84:2299-306
Liao, George P; Harting, Matthew T; Hetz, Robert A et al. (2015) Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med 16:245-55
Arroyo-√Āvila, Mariangel√≠; Santiago-Casas, Yesenia; McGwin Jr, Gerald et al. (2015) Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol 34:1217-23
Chappell, Cynthia L; Okhuysen, Pablo C; Langer-Curry, Rebecca C et al. (2015) Cryptosporidium muris: infectivity and illness in healthy adult volunteers. Am J Trop Med Hyg 92:50-5
Reveille, John D (2014) An update on the contribution of the MHC to AS susceptibility. Clin Rheumatol 33:749-57
Bedi, Supinder S; Walker, Peter A; Shah, Shinil K et al. (2013) Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury. J Trauma Acute Care Surg 75:410-6
Bethi, Siddharth; Dasgupta, Abhijit; Weisman, Michael H et al. (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken) 65:607-14
Ward, Michael M; Learch, Thomas J; Gensler, Lianne S et al. (2013) Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken) 65:257-65
Benjamin-Garner, Ruby; Stotts, Angela (2013) Impact of smoking exposure change on infant birth weight among a cohort of women in a prenatal smoking cessation study. Nicotine Tob Res 15:685-92
Ornstein, Tisha J; Max, Jeffrey E; Schachar, Russell et al. (2013) Response inhibition in children with and without ADHD after traumatic brain injury. J Neuropsychol 7:1-11

Showing the most recent 10 out of 396 publications